argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
argenx (Euronext & Nasdaq: ARGX) announced an Extraordinary General Meeting for shareholders on 18 November 2025 at 14:00 CET at Freshfields offices, Strawinskylaan 10, Amsterdam.
The meeting will consider the proposed adoption of a revised remuneration policy. The formal convocation includes details on in-person attendance, proxy voting, registration requirements and the e-voting system. All meeting documents and the agenda are available on argenx.com and abnamro.com/evoting, and may be inspected at argenx offices or requested by emailing legal@argenx.com. Shareholders are encouraged to vote by electronic proxy as described in the convocation.
argenx (Euronext & Nasdaq: ARGX) ha annunciato una Riunione straordinaria dell'Assemblea degli azionisti per il 18 novembre 2025 alle 14:00 CET presso gli uffici Freshfields, Strawinskylaan 10, Amsterdam.
La riunione esaminerà l'adozione proposta di una politica di remunerazione rivista. L'avviso formale include dettagli sulla partecipazione in presenza, sul voto per procura, sui requisiti di registrazione e sul sistema di voto elettronico. Tutti i documenti della riunione e l'agenda sono disponibili su argenx.com e abnamro.com/evoting, e possono essere ispezionati presso gli uffici argenx o richiesti inviando un'email a legal@argenx.com. Si incoraggia gli azionisti a votare tramite procura elettronica come descritto nell'avviso.
argenx (Euronext & Nasdaq: ARGX) anunció una Junta General Extraordinaria para accionistas para el 18 de noviembre de 2025 a las 14:00 CET en las oficinas de Freshfields, Strawinskylaan 10, Ámsterdam.
La reunión considerará la adopción propuesta de una política de remuneración revisada. La convocatoria formal incluye detalles sobre asistencia en persona, voto por poder, requisitos de registro y el sistema de votación electrónica. Todos los documentos de la reunión y la agenda están disponibles en argenx.com y abnamro.com/evoting, y pueden ser inspeccionados en las oficinas de argenx o solicitados enviando un correo a legal@argenx.com. Se anima a los accionistas a votar por poder electrónico tal como se describe en la convocatoria.
argenx (Euronext & Nasdaq: ARGX)는 주주를 위한 임시 일반 주주 총회를 2025년 11월 18일 14:00 CET에 Freshfields 사무실, Strawinskylaan 10, 암스테르담에서 소집한다고 밝혔다.
회의는 수정된 보상 정책의 채택을 검토할 예정이다. 정식 소집장은 대면 참석, 대리투표, 등록 요건 및 전자투표 시스템에 대한 세부 정보를 포함한다. 모든 회의 문서와 의제는 argenx.com과 abnamro.com/evoting에서 확인 가능하며, argenx 사무실에서 열람하거나 legal@argenx.com으로 이메일을 보내 요청할 수 있다. 주주들은 소집에 설명된 대로 전자 대리투표를 통해 투표하는 것이 권장된다.
argenx (Euronext & Nasdaq : ARGX) a annoncé une Assemblée générale extraordinaire destinée aux actionnaires le 18 novembre 2025 à 14h00 CET aux bureaux Freshfields, Strawinskylaan 10, Amsterdam.
La réunion examinera l'adoption proposée d'une politique de rémunération révisée. L'avis de convocation comprend des détails sur la présence en personne, le vote par procuration, les exigences d'enregistrement et le système de vote électronique. Tous les documents de la réunion et l'ordre du jour sont disponibles sur argenx.com et abnamro.com/evoting, et peuvent être consultés dans les bureaux d'argenx ou demandés en envoyant un e-mail à legal@argenx.com. Les actionnaires sont encouragés à voter par procuration électronique comme décrit dans la convocation.
argenx (Euronext & Nasdaq: ARGX) hat eine außerordentliche Hauptversammlung für Aktionäre angekündigt am 18. November 2025 um 14:00 CET in den Freshfields-Büros, Strawinskylaan 10, Amsterdam.
Die Versammlung wird die vorgeschlagene Einführung einer überarbeiteten Vergütungspolitik prüfen. Die formale Einladung enthält Details zu persönlicher Teilnahme, Stimmrechtsvertretung, Registrierungsvoraussetzungen und dem E-Stimm-System. Alle Sitzungsunterlagen und die Tagesordnung sind verfügbar unter argenx.com und abnamro.com/evoting, und können in den ArgEx-Büros eingesehen oder per E-Mail an legal@argenx.com angefordert werden. Die Aktionäre werden ermutigt, elektronisch per Vollmacht abzustimmen, wie in der Einladung beschrieben.
argenx (Euronext & Nasdaq: ARGX) أعلنت عن اجتماع الهيئة العامة غير العادي للمساهمين في 18 نوفمبر 2025 الساعة 14:00 CET في مكاتب Freshfields، Strawinskylaan 10، أمستردام.
سينظر الاجتماع في اعتماد مقترح لـ سياسة تعويضات معدلة. تتضمن الدعوة الرسمية تفاصيل حول الحضور الشخصي، التصويت بالوكالة، متطلبات التسجيل ونظام التصويت الإلكتروني. جميع مستندات الاجتماع وجدول الأعمال متاحة على argenx.com وabnamro.com/evoting، ويمكن فحصها في مكاتب argenx أو طلبها عبر البريد الإلكتروني legal@argenx.com. يُشجَّع المساهمون على التصويت إلكترونيًا بالوكالة كما هو موضح في الدعوة.
argenx (Euronext & Nasdaq: ARGX) 公布了供股东参加的 非常大会，时间定于 2025年11月18日 14:00 CET，地点在 Freshfields 办公室，Strawinskylaan 10，阿姆斯特丹。
会议将审议拟议通过的 修订后的薪酬政策。正式通知包括关于现场出席、授权表决、登记要求和电子投票系统的细节。所有会议文件和议程可在 argenx.com 与 abnamro.com/evoting 查阅，亦可在 argenx 办公室查阅或通过发送邮件至 legal@argenx.com 请求。股东被鼓励按照通知中的说明通过电子代理投票。
- None.
- None.
October 3, 2025
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.
The shareholders and all other persons with meeting rights are invited to attend the Extraordinary General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.
Agenda
argenx has proposed the adoption of a revised remuneration policy during the meeting. The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
BPetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
When and where is argenx's Extraordinary General Meeting of shareholders (ARGX) scheduled?
What is the main agenda item at argenx's EGM on November 18, 2025 (ARGX)?
How can ARGX shareholders access the EGM convocation and voting information?
Can ARGX shareholders vote by proxy for the November 18, 2025 EGM (ARGX)?
How can I obtain a copy of the EGM agenda and ancillary documents for ARGX?
Is e-voting available for argenx's Extraordinary General Meeting (ARGX)?
